Literature DB >> 7532747

Antiarrhythmic agent amiodarone possesses calcium channel blocker properties.

S P Lubic1, K P Nguyen, B Dave, J C Giacomini.   

Abstract

Amiodarone possesses multiple pharmacologic properties, including peripheral and coronary vasodilatation, negative inotropy, and negative chronotropic and dromotropic effects. These properties are shared by the group of drugs termed calcium channel blockers. We examined the interaction of amiodarone with receptors for the 1,4-dihydropyridine (DHP) calcium blockers in rat and rabbit myocardial membrane particulates. Amiodarone displaced specifically bound [3H]nitrendipine in both rat and rabbit preparations in a competitive, concentration-dependent manner at a single class of binding sites (Ki approximately 0.27 micxroM). Calcium channel activity was determined pharmacologically in a tissue bath with electrically stimulated rabbit right ventricular strips, KCl-induced aortic ring contraction, and 45Ca2+ uptake in K(+)-depolarized cultured rat cardiomyocytes. Amiodarone completely inhibited myocardial contraction (EC50 = 1.7 microM), completely antagonized depolarization-induced aortic ring contraction (EC50 = 24 nM), and significantly reduced (29% vs. control) 45Ca2+ uptake into cultured cells. The calcium channel blocking effects of amiodarone may contribute significantly to its pharmacologic profile.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7532747     DOI: 10.1097/00005344-199424050-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  10 in total

Review 1.  Potentially significant drug interactions of class III antiarrhythmic drugs.

Authors:  Weeranuj Yamreudeewong; Michael DeBisschop; Linda G Martin; Dennis L Lower
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 2.  Amiodarone-induced thyroid disorders: a clinical review.

Authors:  K C Loh
Journal:  Postgrad Med J       Date:  2000-03       Impact factor: 2.401

3.  Propiverine-induced Parkinsonism: a case report and a pharmacokinetic/pharmacodynamic study in mice.

Authors:  H Matsuo; A Matsui; R Nasu; H Takanaga; N Inoue; F Hattori; H Ohtani; Y Sawada
Journal:  Pharm Res       Date:  2000-05       Impact factor: 4.200

4.  Amiodarone use in patients listed for heart transplant is associated with increased 1-year post-transplant mortality.

Authors:  Lauren B Cooper; Robert J Mentz; Leah B Edwards; Amber R Wilk; Joseph G Rogers; Chetan B Patel; Carmelo A Milano; Adrian F Hernandez; Josef Stehlik; Lars H Lund
Journal:  J Heart Lung Transplant       Date:  2016-07-17       Impact factor: 10.247

5.  Discontinuing amiodarone treatment prior to heart transplantation lowers incidence of severe primary graft dysfunction.

Authors:  Benjamin Hoemann; Hiroo Takayama; Douglas L Jennings; Jiho Han; Masahiko Ando; Susan Restaino; Paolo Colombo; Maryjane Farr; Yoshifumi Naka; Koji Takeda
Journal:  Clin Transplant       Date:  2020-01-29       Impact factor: 2.863

Review 6.  Cardiovascular Drugs and Osteoarthritis: Effects of Targeting Ion Channels.

Authors:  Raminta Vaiciuleviciute; Daiva Bironaite; Ilona Uzieliene; Ali Mobasheri; Eiva Bernotiene
Journal:  Cells       Date:  2021-09-28       Impact factor: 6.600

7.  Amiodarone Alters Cholesterol Biosynthesis through Tissue-Dependent Inhibition of Emopamil Binding Protein and Dehydrocholesterol Reductase 24.

Authors:  Luke B Allen; Thiago C Genaro-Mattos; Allison Anderson; Ned A Porter; Károly Mirnics; Zeljka Korade
Journal:  ACS Chem Neurosci       Date:  2020-04-29       Impact factor: 4.418

8.  Spontaneous diffuse vasospasm simultaneously found at left main trunk, left anterior descending, left circumflex and right coronary arteries.

Authors:  Yue-Hai Wang; Guang-Yong Huang; Xiao-Hua Wang
Journal:  J Geriatr Cardiol       Date:  2017-12       Impact factor: 3.327

Review 9.  Handling of Ventricular Fibrillation in the Emergency Setting.

Authors:  Zoltán Szabó; Dóra Ujvárosy; Tamás Ötvös; Veronika Sebestyén; Péter P Nánási
Journal:  Front Pharmacol       Date:  2020-01-29       Impact factor: 5.810

Review 10.  KV11.1, NaV1.5, and CaV1.2 Transporter Proteins as Antitarget for Drug Cardiotoxicity.

Authors:  Magdalena Kowalska; Jacek Nowaczyk; Alicja Nowaczyk
Journal:  Int J Mol Sci       Date:  2020-10-30       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.